These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26870890)

  • 1. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
    Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
    Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
    Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
    Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.
    Wang N; Xu D; Sofiadis A; Höög A; Vukojević V; Bäckdahl M; Zedenius J; Larsson C
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1571-9. PubMed ID: 24758186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
    Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
    Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
    Rodríguez-Antona C; Pallares J; Montero-Conde C; Inglada-Pérez L; Castelblanco E; Landa I; Leskelä S; Leandro-García LJ; López-Jiménez E; Letón R; Cascón A; Lerma E; Martin MC; Carralero MC; Mauricio D; Cigudosa JC; Matias-Guiu X; Robledo M
    Endocr Relat Cancer; 2010 Mar; 17(1):7-16. PubMed ID: 19776290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer.
    Panebianco F; Nikitski AV; Nikiforova MN; Nikiforov YE
    Cancer Med; 2019 Oct; 8(13):5831-5839. PubMed ID: 31408918
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
    Cordero-Barreal A; Caleiras E; López de Maturana E; Monteagudo M; Martínez-Montes ÁM; Letón R; Gil E; Álvarez-Escolá C; Regojo RM; Andía V; Marazuela M; Guadalix S; Calatayud M; Robles-Díaz L; Aguirre M; Cano JM; Díaz JÁ; Saavedra P; Lamas C; Azriel S; Sastre J; Aller J; Leandro-García LJ; Calsina B; Roldán-Romero JM; Santos M; Lanillos J; Cascón A; Rodríguez-Antona C; Robledo M; Montero-Conde C
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32791518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant
    Fotouhi O; Ghaderi M; Wang N; Zedenius J; Kjellman M; Xu D; Juhlin CC; Larsson C
    Epigenetics; 2019 Dec; 14(12):1224-1233. PubMed ID: 31322481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.
    Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X
    Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of TERT and 5-Hydroxymethylcytocine immunohistochemistry in various thyroid carcinomas.
    An HR; Kim WG; Lee YM; Sung TY; Song DE
    Ann Diagn Pathol; 2024 Aug; 71():152290. PubMed ID: 38552304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma.
    Blaker M; de Weerth A; Tometten M; Schulz M; Höppner W; Arlt D; Hoang-Vu C; Dralle H; Terpe H; Jonas L; von Schrenck T
    Eur J Endocrinol; 2002 Jan; 146(1):89-96. PubMed ID: 11751073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR activation in medullary thyroid carcinoma with RAS mutation.
    Lyra J; Vinagre J; Batista R; Pinto V; Prazeres H; Rodrigues F; Eloy C; Sobrinho-Simões M; Soares P
    Eur J Endocrinol; 2014 Nov; 171(5):633-40. PubMed ID: 25163725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.
    McKelvey BA; Umbricht CB; Zeiger MA
    Front Endocrinol (Lausanne); 2020; 11():485. PubMed ID: 32849278
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E.
    Song YS; Park YJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):515-525. PubMed ID: 32981294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustentacular cells occur frequently in the familial form of medullary thyroid carcinoma.
    Matias-Guiu X; Machin P; Pons C; Lagarda E; De Leiva A; Prat J
    J Pathol; 1998 Apr; 184(4):420-3. PubMed ID: 9664909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.